+

WO2013013165A3 - Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus - Google Patents

Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus Download PDF

Info

Publication number
WO2013013165A3
WO2013013165A3 PCT/US2012/047638 US2012047638W WO2013013165A3 WO 2013013165 A3 WO2013013165 A3 WO 2013013165A3 US 2012047638 W US2012047638 W US 2012047638W WO 2013013165 A3 WO2013013165 A3 WO 2013013165A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
lupus erythematosus
systemic lupus
therapeutic inhibition
lna compounds
Prior art date
Application number
PCT/US2012/047638
Other languages
French (fr)
Other versions
WO2013013165A2 (en
Inventor
Marianthi Kiriakidou
Barry GARCHOW
Sakari Kauppinen
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2013013165A2 publication Critical patent/WO2013013165A2/en
Publication of WO2013013165A3 publication Critical patent/WO2013013165A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention encompasses compositions of LNA antimiRs as well as methods of their use for the regulation of miR-21 expression. The present invention encompasses methods of treating diseases where miR-21 is up-regulated. An example of such a disease is Systemic Lupus Erythematosus (SLE).
PCT/US2012/047638 2011-07-21 2012-07-20 Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus WO2013013165A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161510283P 2011-07-21 2011-07-21
US61/510,283 2011-07-21
US201161511854P 2011-07-26 2011-07-26
US61/511,854 2011-07-26

Publications (2)

Publication Number Publication Date
WO2013013165A2 WO2013013165A2 (en) 2013-01-24
WO2013013165A3 true WO2013013165A3 (en) 2013-04-11

Family

ID=47558744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/047638 WO2013013165A2 (en) 2011-07-21 2012-07-20 Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus

Country Status (1)

Country Link
WO (1) WO2013013165A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181547B2 (en) 2011-04-25 2015-11-10 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating MIR-21 activity
PL398796A1 (en) * 2012-04-11 2013-10-14 Krzysztof Selmaj The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis
SG11201406931XA (en) 2012-04-25 2014-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (en) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Methods for treatment of alport syndrome
JOP20200228A1 (en) 2015-12-21 2017-06-16 Novartis Ag Compositions and methods for decreasing tau expression
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286234A1 (en) * 2006-04-03 2010-11-11 Joacim Elmen Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides
US20100298410A1 (en) * 2007-10-04 2010-11-25 Santaris Pharma A/S MICROMIRs
US20100322909A1 (en) * 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy
US20110118339A1 (en) * 2008-01-18 2011-05-19 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286234A1 (en) * 2006-04-03 2010-11-11 Joacim Elmen Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides
US20100298410A1 (en) * 2007-10-04 2010-11-25 Santaris Pharma A/S MICROMIRs
US20110118339A1 (en) * 2008-01-18 2011-05-19 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and uses thereof
US20100322909A1 (en) * 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FLUITER ET AL.: "Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.", MOL. BIOSYST., vol. 5, no. 8, 2009, pages 838 - 843 *
GARCHOW ET AL.: "Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice.", EMBO MOL MED., vol. 3, no. 10, 1 September 2011 (2011-09-01), pages 605 - 615 *
OBAD ET AL.: "Silencing of microRNA families by seed-targeting tiny LNAs.", NAT GENET., vol. 43, no. 4, 20 March 2011 (2011-03-20), pages 371 - 378 *
QIAGEN.: "hsa-mir-21", 2008, Retrieved from the Internet <URL:https://www.qiagen.com/geneglobe/miprimerview.aspx?keepresult=true&producttype=88ID=MS00009086#ProductList> [retrieved on 20121217] *
ROSSI.: "Stopping RNA interference at the seed.", NAT GENET., vol. 43, no. 4, 29 March 2011 (2011-03-29), pages 288 - 289 *
STAGAKIS ET AL.: "Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression.", ANN RHEUM DIS., vol. 70, no. 8, 20 May 2011 (2011-05-20), pages 1496 - 1506 *

Also Published As

Publication number Publication date
WO2013013165A2 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
IL263843B (en) Antisense compounds containing an antisense oligonucleotide complementary to nucleic acid transcription and compositions containing them for the treatment of related metabolic diseases
WO2013134336A3 (en) Inhibition of adaptor associated kinase 1 for the treatment of pain
MX339873B (en) Serine/threonine kinase inhibitors.
CL2015001442A1 (en) Method for treating lung diseases comprising the use of compounds derived from obetolic acid.
WO2013181579A3 (en) Tetrahydropyrazolopyrimidine compounds
WO2013013165A3 (en) Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
EP2768525A4 (en) FORMANTS OF STERILE STABILIZED BY METALLIC IONS
WO2012020307A3 (en) Therapeutic uses of microvesicles and related micrornas
PT2925757T (en) Compounds and compositions for the treatment of parasitic diseases
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
PH12016501941B1 (en) Use of heterocyclic compounds for controlling nematodes
WO2012136383A8 (en) Preparation of sitagliptin intermediates
EP3087184A4 (en) Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
IN2014DN05772A (en)
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
WO2012061754A3 (en) Compounds and methods for treating autoimmune diseases
PT2806743T (en) Antifungal formulations comprising an extract from rheum roots for the treatment of plant diseases
WO2012048265A3 (en) Methods of treating inflammation
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
EP2994460A4 (en) Compounds for treatment of angiogenesis-mediated diseases
HK1194665A1 (en) Compositions for the treatment of neurologic disorders
WO2012112674A3 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
EP2681207A4 (en) Heterocyclic compounds for the inhibition of pask
PL2552244T3 (en) Inhibition of undesired sensory effects by the compound camphor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12814291

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12814291

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载